Though Sequencers Improve Performance, $10,000 Genome Remains Elusive in '08, Survey Finds
January 13, 2009
Though Sequencers Improve Performance, $10,000 Genome Remains Elusive in '08, Survey Finds
The survey, conducted by In Sequence, also showed that many users of second-gen sequencers made by Illumina, 454, and ABI struggled with technical problems.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sanofi, Curie Institute Collaborate on Sequencing-based Ovarian Cancer
June 19, 2013 / GenomeWeb Daily News - GATC Biotech Launches One-Week Diagnostic Exome, but Clinical Interpretation is Pending
June 19, 2013 / Clinical Sequencing News - University of Cologne Combines AmpliSeq, MiSeq for Cancer Dx; Looks to Validate Qiagen Panels
June 19, 2013 / Clinical Sequencing News - Life Tech Adds to Clinical NGS Partnerships With University of Buffalo, Empire Genomics Deal
June 19, 2013 / Clinical Sequencing News - In Print: Last Week's Clinical Sequencing Papers of Note
June 19, 2013 / Clinical Sequencing News